Propranolol in Post Traumatic Stress Disorder (Reductrauma)

This is an interventional treatment trial for Post-Traumatic Stress Disorder focused on measuring adults, PTSD, trauma, AZF, propranolol, reconsolidation, Post traumatic stress disorder, chronic form, PTSD (Post-Traumatic Stress Disorder) Read More

Inclusion Criteria:

• 18-65 years old
• Suffer from AZF-related PTSD (PCL score more than 44)
• Sign consent form
• Subjects must have health coverage.

Exclusion Criteria:

• Not diagnosed with current, chronic AZF-related PTSD
• Age < 18 or > 65
• Systolic blood pressure < 100 mm Hg

• Medical condition that contraindicates the administration of propranolol, e.g., history of congestive heart failure, heart block, insulin-requiring diabetes, chronic bronchitis, emphysema, or asthma. With regard to asthma, because many persons who say they have had an asthma attack, especially as a child, may only have had hay fever, another allergy, or another non-asthmatic episode, a blanket exclusion criterion may be overly restrictive. Therefore, asthma attacks will only be exclusionary if they:

  • occurred within the past ten years,
  • occurred at any time in life if induced by a β-blocker, or
  • are currently being treated, regardless of the date of last occurrence.

Cardiological consultation will be obtained as necessary.

• Previous adverse reaction to, or non-compliance with, a β-blocker
• Current use of medication that may involve potentially dangerous interactions with propranolol, including, other β-blockers, antiarrhythmics, calcium channel blockers, and potent P450 2D6 inhibitors, e.g., fluoxetine, paroxetine, miconazole, sulconazole, metoclopramide, quinidine, ticlopidine, and ritonavir.
• Contraindicating psychiatric condition, including lifetime or current psychotic, bipolar, melancholic, or substance dependence or abuse disorder; suicidality.
• Initiation of, or change in, psychotropic medication within the previous two months. For subjects receiving stable doses of pharmacotherapy, they and their providers will be asked not to change the regimen except in clinically urgent circumstances; if this becomes necessary, a decision will be made on a case-by-case basis with regard to retaining the subject or terminating participation.
• Current participation in any psychotherapy (other than strictly supportive). Subjects will be asked not to initiate psychotherapy during the course of the proposed study except in clinically urgent circumstances; if this becomes necessary, a decision will be made on a case-by-case basis with regard to retaining the subject or terminating participation.
• Inability to understand the study's procedures, risks, and side effects, or to otherwise give informed consent for participation
• Does not understand French